We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

68 hedge funds and large institutions have $108M invested in Aurinia Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

10% more funds holding

Funds holding: 62 → 68 (+6)

0.32% more ownership

Funds ownership: 28.06% → 28.38% (+0.32%)

27% less capital invested

Capital invested by funds: $147M → $108M (-$39M)

71% less call options, than puts

Call options by funds: $865K | Put options by funds: $2.99M

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
17
Reduced
15
Closed
14
Calls
$865K
Puts
$2.99M
Net Calls
-$2.12M
Net Calls Change
+$1.29M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4M
2
PC
Polar Capital
United Kingdom
+$3.78M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.98M
4
Franklin Resources
Franklin Resources
California
+$2.3M
5
Goldman Sachs
Goldman Sachs
New York
+$1.77M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.74M
2
CLCM
Crawford Lake Capital Management
New Jersey
-$2.86M
3
RG
Redmile Group
California
-$2.08M
4
SC
Sculptor Capital
New York
-$1.16M
5
Morgan Stanley
Morgan Stanley
New York
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$21.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$21.8M -$5.74M -1,034,350 -18%
PC
3
Polar Capital
United Kingdom
$10.4M +$3.78M +681,648 +42%
O
4
OrbiMed
New York
$8.14M – – –
Franklin Resources
5
Franklin Resources
California
$7.54M +$2.3M +414,400 +33%
VC
6
Vivo Capital
California
$5.5M – – –
Goldman Sachs
7
Goldman Sachs
New York
$5.41M +$1.77M +319,639 +37%
BlackRock
8
BlackRock
New York
$3.26M +$4M +719,713 New
Alyeska Investment Group
9
Alyeska Investment Group
Illinois
$2.63M -$555K -100,000 -15%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$2.43M +$2.98M +537,000 New
Balyasny Asset Management
11
Balyasny Asset Management
Illinois
$2.27M – – –
Hudson Bay Capital Management
12
Hudson Bay Capital Management
Connecticut
$2.04M +$416K +75,000 +20%
Morgan Stanley
13
Morgan Stanley
New York
$1.67M -$1.13M -203,363 -36%
AIC
14
AWM Investment Company
New York
$1.61M +$11.2K +2,020 +0.6%
A
15
Abingworth
United Kingdom
$1.14M – – –
Ameriprise
16
Ameriprise
Minnesota
$1.07M +$143K +25,784 +12%
Group One Trading
17
Group One Trading
Illinois
$1.03M -$192K -34,598 -13%
IIM
18
Ironwood Investment Management
Massachusetts
$842K -$35K -6,312 -3%
KAM
19
Kazazian Asset Management
Florida
$707K +$89.9K +16,189 +12%
Creative Planning
20
Creative Planning
Kansas
$683K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$636K -$929K -167,316 -54%
Citadel Advisors
22
Citadel Advisors
Florida
$577K +$641K +115,389 +970%
UBS Group
23
UBS Group
Switzerland
$538K +$144K +26,000 +28%
CS
24
Candriam SCA
Luxembourg
$535K – – –
Swiss National Bank
25
Swiss National Bank
Switzerland
$421K +$513K +92,400 New
1
2 3 4

AUPH Hedge Fund Activity: Q4 2017 in Review

68 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2017, worth a combined $108M — down 27% from $147M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AUPH positions and 14 closed out — a net gain of 6 holders — while 17 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $4M. The largest seller was Fidelity Investments, cutting an estimated $5.74M.

  • 68 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2017, up from 62 in Q3 2017.
  • Funds reported $108M of Aurinia Pharmaceuticals stock for Q4 2017, down 27% quarter-over-quarter.
  • 20 funds opened new Aurinia Pharmaceuticals positions in Q4 2017 and 14 closed out, a net change of +6 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2017 was BlackRock, an estimated $4M added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $5.74M sold.

Based on aggregated 13F filings for Q4 2017.